Skip to content

The Effect of PERT on Patients Undergoing Pancreaticoduodenectomy

The Effect of PERT on Postoperative Complications and Physiological Status in Patients Undergoing Pancreaticoduodenectomy

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06119880
Enrollment
100
Registered
2023-11-07
Start date
2023-11-01
Completion date
2025-12-31
Last updated
2023-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Enzyme Replacement Therapy, Pancreatic Exocrine Insufficiency, Pancreaticoduodenectomy

Brief summary

A comprehensive perioperative nutrition management plan for pancreaticoduodenectomy, primarily based on pancreatic enzyme replacement therapy (PERT). A prospective randomized controlled study was conducted to comprehensively analyze the perioperative nutritional status of patients undergoing pancreaticoduodenectomy, with the aim of exploring: 1. The effect of PERT on postoperative complications and physiological status after pancreaticoduodenectomy; 2. The efficacy of PERT treatment on clinical symptoms, nutritional indicators, and quality of life (QOL) related to pancreatic exocrine dysfunction (PEI) after pancreaticoduodenectomy; 3. The personalized full process nutrition management strategies based on risk factor stratification.

Interventions

pancreatic enzyme replacement therapy

OTHERRoutine treatment plan

Routine treatment plan without PERT

Sponsors

Ruijin Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Gender unlimited, 18-80 years old; * Patients undergoing pancreaticoduodenectomy due to various benign or malignant diseases; * Voluntary testing with informed consent.

Exclusion criteria

* Pregnant women and lactating women * Patients with distant metastasis based on tumor staging before surgery; * Tumor recurrence; * Refuse to sign the consent form.

Design outcomes

Primary

MeasureTime frameDescription
Abdominal Skeletal Muscle Index (SMI)8 weeks post-operationMeasurement of abdominal skeletal muscle area at the third lumbar spine plane using abdominal plain scan CT and comparison of baseline level SMI change rate.

Secondary

MeasureTime frameDescription
Postoperative complications8 weeks post-operationpostoperative pancreatic fistula, delayed gastric emptying, postoperative hypoproteinemia;
Nutritional indicators8 weeks post-operationPatient generated subjective global assessment (PG-SGA);

Countries

China

Contacts

Primary ContactWeishen WANG, DR
peanutswey@hotmail.com64370045

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026